20-OCT-2026 6:10

ERLYTX ACCRUAL REPORT - Open and Recently Closed Studies

SWOG/
Support
STUDY R
E
G
O
P
E
N
ARM ACCR.
GOAL
TOTAL
REGS.
REGS.
LAST
12
Month
REGS.
LAST
6
Month
REGS.
LAST
3
Month
REGS.
LAST
30
DAYS
REGS.
LAST
7
DAYS
DATE OF
FIRST
REG.
# of
ACT.
INSTs
# of
CURR
IRBs
SWOG S2012-Extrapulm NEC, Stg IV, Combo Chemo +/- Atezo 1 Y 1 Platinum/Etoposide + Atezo Induction + Maintenance 189 59 14 5 2 2 1 06/28/2022 275 82
        2 Platinum/Etoposide + Atezo Induction   53 13 4 0 0 0      
        3 Platinum/Etoposide Only   58 19 11 1 1 0      
            170 46 20 3 3 1      
 
  SN2426-cSCC, IC Met/Inop, Amivantamab v Cetuximab 1 Y 1 Amivantamab and hyaluronidase (Safety Run-in) 86 11 11 8 4 0 0 03/23/2026 126 35
            11 11 8 4 0 0      
 
  21CTP.HN01-HN, Recur/Met, Amivantamab + Chemo 1 Y 1 Amivantamab + Carboplatin + Paclitaxel 50 11 11 9 5 2 1 03/25/2026    
            11 11 9 5 2 1      
 
Yes A071401-Prog Meningiomas,SMO/AKT/NF2 Inhib 0 E Total Registrations   53 1 0 0 0 0 02/22/2016 309 88
            53 1 0 0 0 0      
 
    1 E Total Registrations   9 0 0 0 0 0 02/22/2016    
            9 0 0 0 0 0      
 
No AGCT1531-Mult, Stg I-IV, Carbo vs Cisp, Ped &Adult 1 E Total Registrations   6 2 1 1 1 1 10/07/2021 226 115
            6 2 1 1 1 1      
 
  AGCT1532-Inter/Poor Met GCTs, Accel v Std BEP Chemo 1 T Total Registrations   5 0 0 0 0 0 12/13/2019 214 91
            5 0 0 0 0 0      
 
  EA7211-Sarc, Hi-Risk RetroPeritoneal, Neo+Sur 1 E Total Registrations   2 2 0 0 0 0 03/24/2026 94 16
            2 2 0 0 0 0      
 
  EAY191-ComboMATCH 1 E Total Registrations   22 2 1 0 0 0 08/03/2023 325 118
            22 2 1 0 0 0      
 

20-OCT-2026 6:10

ERLYTX Open Studies with No Registrations

Study Registration/Phase Open Date # of
ACT.
INSTs
# of
CURR
IRBs
S2505 Sarcoma, Stg II-IIIB, Surg + Short vs Std RT 1 Randomization 06-Jul-26 73 34
AGCT1531 Mult, Stg I-IV, Carbo vs Cisp, Ped &Adult 2 Late Randomization Callback 08-May-17 226 115
EAY191 ComboMATCH 2 Re-Screening 06-Mar-23 325 118